Synapse 3D Base Tools (V7.0)

The Synapse 3D Base Tools (V7.0) is a Class II medical imaging software designed to assist trained professionals in comprehensive image interpretation and treatment planning, processing DICOM-compliant images from various modalities. Its scientific basis lies in advanced algorithms for 2D/3D visualization, multi-planar reconstruction, image fusion, and segmentation, providing specialized analysis features for anatomical structures, supported by performance testing for substantial equivalence.

The Synapse 3D Base Tools (V7.0), developed by FUJIFILM Corporation, received a substantial equivalence determination from the U.S. Food & Drug Administration on May 21, 2025, classifying it as a Class II medical image management and processing system. This regulatory clearance permits its marketing, subject to standard controls such as annual registration, device listing, and adherence to good manufacturing practices, indicating its readiness for clinical use. Its determination of substantial equivalence was supported by performance testing, including data from US patient populations, and compliance with safety and cybersecurity standards. The software is designed for trained medical professionals to assist in reading, interpreting, reporting, and treatment planning across various medical imaging modalities like CT, MR, and US, specifically excluding primary diagnostic interpretation for mammography. Its functionality includes 2D and 3D viewing, multi-planar reconstructions, image fusion, and segmentation, incorporating new features such as Pancreas Analysis, Rectal Analysis, and a Segmentation Viewer.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. What specific improvements or novel methodologies in V7.0 led to the new Pancreas Analysis and Rectal Analysis features, and how do they enhance diagnostic accuracy or treatment planning compared to previous versions or competing systems?; While substantial equivalence was determined, what were the specific performance metrics and validation studies, including quantitative results from US patient populations, that demonstrated its safety, efficacy, and accuracy for different imaging modalities?; How does the Synapse 3D Base Tools (V7.0) integrate with existing hospital PACS systems and electronic health records, and what are its capabilities for data sharing and interoperability in a multi-vendor clinical environment?; Beyond the stated exclusion for mammography, are there other imaging contexts or disease states where the software's use is contraindicated or where its performance has known limitations?; What are the long-term support plans, including software updates, cybersecurity protocols, and training programs, that FUJIFILM Corporation will provide to ensure the sustained safe and effective use of Synapse 3D Base Tools (V7.0) in clinical settings?